BridgeBio Pharma

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio was founded in 2015 by Neil Kumar and Nishanth Allegatu. The company initially focused on genetic disease research and has spun out more than 20 companies in the five years since its formation. BridgeBio’s portfolio companies are developing treatments for an array of inherited diseases and cancers.

To improve quality of life for patients by translating the promise of genetics into transformative medicines.

BridgeBio strives to be a key player in tackling the world’s most challenging diseases.The company partners with top academic research institutions, industry leaders, and venture investors to develop a portfolio of novel therapies.

To improve quality of life for patients by translating the promise of genetics into transformative medicines.

BridgeBio Pharma

Share

Contacts

Follow Us

BridgeBio Pharma

Share

Contacts

Follow Us